ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 112 positions · Total reported value $4.91B · Top-10 concentration 51.1% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 62.8% · 26 new · 32 cut · 33 exited

Active Share (vs S&P 500): 95.4% · vs QQQ: 99.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -11.1% · vs SPY -13.2% · Prev Value $4.97B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.2% · vs SPY -6.3% · Latest Value $4.91B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, ORBIMED ADVISORS LLC disclosed 112 equity positions with a combined reported value of $4.91B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were EWTX ($630.05M), VNDA ($482.66M), ELVN ($310.64M). By sector, the heaviest allocations are Health Care 91.9%, Industrials 2.2%. Versus the prior quarter, allocation shifted toward Industrials (+0.7pp) and away from Other (-0.6pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 26 new positions, trimmed 32 and fully exited 33, a turnover rate of 62.8% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q3 2026 were VNDA ($482.66M), GRTX ($77.46M), ABBV ($67.91M).

Of the 33 positions fully exited versus the prior quarter, the largest were DYN ($71.86M), CGON ($69.12M), BSX ($63.30M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VNDA VANDA PHARMACEUTICALS INC · $482.66M
  • GRTX ELECTRA THERAPEUTICS INC · $77.46M
  • ABBV ABBVIE INC · $67.91M
  • CDNA CAREDX INC · $60.76M
  • ABT ABBOTT LABORATORIES · $57.22M
  • JAZZ JAZZ PHARMACEUTICALS PLC · $30.35M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $27.98M
  • CELC CELCUITY INC · $25.01M

Fully Exited (vs previous quarter)

  • DYN DYNE THERAPEUTICS INC · prev qtr: $71.86M
  • CGON CG ONCOLOGY INC · prev qtr: $69.12M
  • BSX BOSTON SCIENTIFIC CORP · prev qtr: $63.30M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $53.87M
  • BMY BRISTOL-MYERS SQUIBB CO · prev qtr: $53.30M
  • SYK STRYKER CORPORATION · prev qtr: $50.09M
  • XBI SPDR SERIES TRUST · prev qtr: $47.48M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $37.38M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased positions (26 new) and total value, with a focus on Health Care (100% of top-10). Weight changes suggest tactical adjustments rather than broad sector rotation. 2. Key moves: - Added: MRK (+42.6% shares, weight +1.09pp). - Reduced: MBX (-10.3% shares, weight -0.14pp). - New: VNDA (9.82% weight). 3. Portfolio structure: Active, concentrated (112 positions), high Health Care bias. Risk appetite appears moderate, with mix of large caps (LLY, MRK) and biotech (EWTX, ELVN). 4. Per-holding one-liner: - EWTX: Biotech (unverified). - VNDA: Neurology-focused pharma (unverified). - ELVN: Biotech (unverified). - LLY: Large-cap pharma. - SVA: Vaccines (unverified). - MBX: Biotech (unverified). - MRK: Large-cap pharma. - GH: Cancer diagnostics (unverified). - AVBP: Biotech (unverified). - CRVS: Oncology biotech (unverified). 5. Style summary: Tactically added Merck while trimming a small biotech, expanding into new biotech names within a concentrated, Health Care-focused active strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:41

Sector Allocation

Health Care 91.9%
Other 5.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 15.52M $630.05M 12.82%
12.82%
Hold
2 24.21M $482.66M 9.82%
9.82%
New
3 6.78M $310.64M 6.32%
6.32%
Hold
4 257.90K $298.41M 6.07%
6.07%
Hold
5 2.72M $195.50M 3.98%
3.98%
Hold
6 3.07M $180.25M 3.67%
3.67%
Reduce
7 946.10K $137.48M 2.80%
2.80%
Add
8 584.10K $104.18M 2.12%
2.12%
Hold
9 3.03M $91.67M 1.86%
1.86%
Hold
10 7.17M $82.54M 1.68%
1.68%
Hold
11 199.70K $82.54M 1.68%
1.68%
Reduce
12 3.12M $82.52M 1.68%
1.68%
Add
13 120.40K $81.28M 1.65%
1.65%
Add
14 219.00K $80.39M 1.64%
1.64%
Add
15 345.20K $78.65M 1.60%
1.60%
Add
16 6.89M $77.46M 1.58%
Form 4 · 22 →
1.58%
New
17 75.18K $72.09M 1.47%
1.47%
Reduce
18 834.90K $72.07M 1.47%
1.47%
Hold
19 259.60K $67.91M 1.38%
1.38%
New
20 2.19M $67.17M 1.37%
1.37%
Reduce
21 3.00M $66.69M 1.36%
1.36%
Hold
22 2.00M $64.16M 1.31%
1.31%
Add
23 379.30K $61.78M 1.26%
1.26%
Reduce
24 934.80K $60.76M 1.24%
1.24%
New
25 200.40K $58.36M 1.19%
1.19%
Reduce
26 579.00K $57.22M 1.16%
1.16%
New
27 127.80K $48.76M 0.99%
0.99%
Reduce
28 6.31M $43.01M 0.88%
0.88%
Hold
29 1.33M $41.62M 0.85%
0.85%
Reduce
30 988.49K $40.16M 0.82%
0.82%
Add
31 96.80K $39.36M 0.80%
0.80%
Reduce
32 408.00K $38.85M 0.79%
0.79%
Add
33 1.45M $36.55M 0.74%
0.74%
Reduce
34 8.29M $35.72M 0.73%
0.73%
Hold
35 4.13M $34.14M 0.69%
0.69%
Hold
36 97.70K $32.49M 0.66%
0.66%
Add
37 229.86K $31.70M 0.65%
0.65%
Add
38 170.88K $31.51M 0.64%
0.64%
Add
39 131.10K $30.35M 0.62%
0.62%
New
40 5.69M $30.01M 0.61%
0.61%
Hold
41 80.18K $29.73M 0.60%
0.60%
Add
42 1.40M $29.04M 0.59%
0.59%
Add
43 1.68M $27.98M 0.57%
0.57%
New
44 314.50K $25.01M 0.51%
0.51%
New
45 278.00K $23.99M 0.49%
0.49%
New
46 384.52K $23.28M 0.47%
0.47%
Reduce
47 5.68M $22.21M 0.45%
0.45%
Hold
48 150.00K $21.13M 0.43%
0.43%
Add
49 1.56M $20.96M 0.43%
0.43%
Reduce
50 3.33M $20.93M 0.43%
0.43%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 22% of its Top-10 each quarter and backtests at F1 78% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 78% · recall 78% · F1 78% · avg rank error 1.9 · Top-10 turnover 22%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% SVA · LLY · BIIB · BSX · ISRG · EWTX · BMRN · RYZB · ELVN · MRK SVA · LLY · EWTX · BSX · ISRG · BIIB · MRK · JANX · ELVN · THC
2024-Q2 100% 100% 100% SVA · LLY · EWTX · BSX · BIIB · ISRG · MRK · JANX · ELVN · THC SVA · LLY · EWTX · BSX · ISRG · BIIB · ELVN · MRK · THC · JANX
2024-Q3 90% 90% 90% SVA · LLY · EWTX · BSX · ISRG · BIIB · ELVN · MRK · THC · JANX EWTX · SVA · LLY · BSX · ISRG · ELVN · BIIB · MRK · THC · SYK
2024-Q4 70% 70% 70% EWTX · SVA · LLY · BSX · ISRG · ELVN · BIIB · MRK · SYK · THC EWTX · SVA · BSX · LLY · ISRG · ELVN · NBIX · SYK · SRPT · ARGX
2025-Q1 80% 80% 80% EWTX · SVA · BSX · LLY · ISRG · ELVN · NBIX · SRPT · SYK · ARGX SVA · EWTX · BSX · LLY · ELVN · ISRG · SYK · ARGX · EW · UNH
2025-Q2 90% 90% 90% SVA · EWTX · BSX · LLY · ELVN · ISRG · SYK · ARGX · EW · NBIX SVA · BSX · LLY · EWTX · ELVN · ISRG · SPRY · SYK · EW · ARGX
2025-Q3 80% 80% 80% SVA · BSX · LLY · EWTX · ELVN · ISRG · SPRY · SYK · EW · ARGX EWTX · LLY · SVA · ELVN · ALNY · SYK · EW · ISRG · ARGX · SION
2025-Q4 70% 70% 70% EWTX · LLY · SVA · ELVN · ALNY · SYK · EW · ISRG · ARGX · SION EWTX · LLY · BSX · SVA · UPB · ISRG · SION · MBX · ARGX · ELVN
2026-Q1 70% 70% 70% EWTX · LLY · BSX · SVA · UPB · ISRG · SION · MBX · ELVN · ARGX EWTX · ELVN · MDXH · LLY · SVA · BSX · SION · AZN · MYGN · MBX
2026-Q2 60% 60% 60% EWTX · ELVN · MDXH · LLY · SVA · BSX · AZN · SION · MYGN · EW EWTX · ELVN · LLY · MBX · SVA · AZN · GPCR · SION · CRVS · AVBP
2026-Q3 ★ 70% 70% 70% EWTX · ELVN · LLY · AZN · MBX · SVA · GPCR · SION · AVBP · CRVS EWTX · VNDA · ELVN · LLY · SVA · MBX · MRK · GH · AVBP · CRVS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings26 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-2.18%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+14.84%vs benchmark
Barra annualised vol20.2%Model estimate
Realised vol26.6%Annualised in window
Weighted beta0.58Raw exposure
Factor / specific risk71% / 29%Share of variance
Top-10 concentration73.2%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16ORBIMED ADVISORS LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-2.18%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+14.84%Portfolio − benchmark
Arithmetic return sum-1.74%Difference vs compounded is the cross term
Weighted raw beta0.58Weighted holding betas
Realised volatility (annualised)26.63%Daily returns in window
Barra model volatility (annualised)20.16%Factor + specific
Factor share of variance70.9%Barra factors
Specific share of variance29.1%Stock residuals
Reported value$1.48B13F long US equity

2. Return attribution

The -1.74% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +0.43% 24.5%
Momentum & Growth 3 -2.85% -163.2%
Volatility & Tail Risk 7 +2.16% 123.6%
Industry 12 +6.58% 376.9%
Specific 1 -8.06% -461.8%
Return attribution (style + industry, %)-6.9-3.5+0.0+3.5+6.9Consumer Staples+0.14Short-term Reversal-0.15Non-linear Size+0.25Growth+0.40Leverage (Downside Vol)+0.41Max Drawdown-0.46Beta-1.31Mid Cap-1.48Turnover+1.73Skewness-2.57Residual Volatility+2.72Momentum-3.10Kurtosis+3.50Health Care+6.42
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +0.92 +6.98% +6.42% 368.2%
Kurtosis Style +0.47 +7.51% +3.50% 200.5%
Residual Volatility Style +0.82 +3.29% +2.72% 155.7%
Turnover Style -0.36 -4.80% +1.73% 99.0%
Leverage (Downside Vol) Style -0.24 -1.71% +0.41% 23.3%
Growth Style +0.23 +1.75% +0.40% 22.8%
Non-linear Size Style +0.25 +1.01% +0.25% 14.2%
Consumer Staples Industry +0.01 +12.82% +0.14% 7.8%
Amihud Illiquidity Style +0.26 -0.45% -0.12% -6.7%
Historical Volatility Style +0.01 -14.00% -0.13% -7.4%
Short-term Reversal Style -0.17 +0.87% -0.15% -8.4%
Max Drawdown Style +0.26 -1.76% -0.46% -26.4%
Beta Style -0.29 +4.44% -1.31% -74.9%
Mid Cap Style +0.77 -1.94% -1.48% -85.0%
Skewness Style +0.58 -4.39% -2.57% -147.2%
Momentum Style +0.77 -4.00% -3.10% -177.6%
Specific Specific — — -8.06% -461.8%

3. Risk attribution

Annualised volatility is 20.16%; factor risk explains 70.9% of variance and specific risk 29.1%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-56.0-28.0+0.0+28.0+56.0Beta-3.00Short-term Reversal-0.65Max Drawdown-0.64Amihud Illiquidity-0.42Consumer Staples+0.34Growth+1.20Skewness+1.21Kurtosis+1.45Industrials+1.98Residual Volatility+2.04Mid Cap+4.31Momentum+11.18Specific+29.10Health Care+51.84
Factor Type Exposure Share of variance Vol contribution Share of vol
Health Care Industry +0.92 51.8% +10.45% 10.4%
Specific Specific — 29.1% +5.86% 5.9%
Momentum Style +0.77 11.2% +2.25% 2.2%
Mid Cap Style +0.77 4.3% +0.87% 0.9%
Residual Volatility Style +0.82 2.0% +0.41% 0.4%
Industrials Industry +0.07 2.0% +0.40% 0.4%
Kurtosis Style +0.47 1.4% +0.29% 0.3%
Skewness Style +0.58 1.2% +0.24% 0.2%
Growth Style +0.23 1.2% +0.24% 0.2%
Consumer Staples Industry +0.01 0.3% +0.07% 0.1%
Amihud Illiquidity Style +0.26 -0.4% -0.08% -0.1%
Max Drawdown Style +0.26 -0.6% -0.13% -0.1%
Short-term Reversal Style -0.17 -0.7% -0.13% -0.1%
Beta Style -0.29 -3.0% -0.60% -0.6%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-0.9-0.10.71.62.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.02 +2.10 -2.12
Non-linear Size +0.24 +1.68 -1.43
Mid Cap +0.77 +0.13 +0.64
Beta -0.29 +1.29 -1.59
Momentum +0.78 +0.72 +0.06
Short-term Reversal -0.17 -0.64 +0.48
Residual Volatility +0.82 -0.40 +1.23
Historical Volatility +0.01 +0.86 -0.85
Liquidity +0.04 +0.11 -0.08
Amihud Illiquidity +0.26 +1.16 -0.89
Turnover -0.36 +0.21 -0.57
Growth +0.23 +0.58 -0.36
Leverage (Downside Vol) -0.24 +0.14 -0.38
Skewness +0.58 +0.24 +0.35
Kurtosis +0.47 +0.21 +0.25
Max Drawdown +0.26 -0.08 +0.35

5. Industry allocation & Brinson

Industry allocation (weight, %)-9.218.446.073.6101.2Information TechnologyCommunication ServicesUtilitiesConsumer DiscretionaryConsumer StaplesIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 1.1% 0.8% +3.38% +15.26% +0.07% -0.10% -0.03% -0.09%
Industrials 7.0% 11.1% +2.60% +4.36% -0.89% -0.20% +0.07% -0.30%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Health Care 92.0% 1.7% -1.12% +8.29% +22.94% -0.16% -8.49% -1.18%
Total +23.78% +16.00% -24.90% +14.88%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
LLY ELI LILLY & CO Health Care 20.17% +23.73% +4.79% Hold
MRK MERCK & CO INC Health Care 9.29% -0.58% -0.05% Add
GH GUARDANT HEALTH INC Health Care 7.04% -19.25% -1.35% Hold
AVBP ARRIVENT BIOPHARMA INC Health Care 6.20% -61.82% -3.83% Hold
NTRA NATERA INC Health Care 5.58% -30.20% -1.69% Reduce
TMO THERMO FISHER SCIENTIFIC INC Industrials 5.49% +2.41% +0.13% Add
UNH UNITEDHEALTH GROUP INC Health Care 5.43% +12.24% +0.66% Add
ARGX ARGENX SE Health Care 4.87% -0.83% -0.04% Reduce
ABBV ABBVIE INC Health Care 4.59% +12.60% +0.58% New
ODTX ODYSSEY THERAPEUTICS INC Health Care 4.51% -12.87% -0.58% Hold
AZN ASTRAZENECA PLC Health Care 4.18% +13.96% +0.58% Reduce
ABT ABBOTT LABORATORIES Health Care 3.87% +8.72% +0.34% New
HUM HUMANA INC Health Care 3.30% +20.88% +0.69% Reduce
GPCR STRUCTURE THERAPEUTICS INC Health Care 2.81% -40.61% -1.14% Reduce
ISRG INTUITIVE SURGICAL INC Health Care 2.66% +7.65% +0.20% Reduce
WST WEST PHARMACEUTICAL SVSC INC Health Care 2.01% +12.69% +0.26% Add
DXCM DEXCOM INC Health Care 1.62% -5.42% -0.09% New
PTGX PROTAGONIST THERAPEUTICS INC Health Care 1.43% -11.40% -0.16% Add
WAT WATERS CORP Industrials 1.20% +3.19% +0.04% Hold
CVS CVS HEALTH CORP Consumer Staples 1.06% +3.38% +0.04% New
Contribution rank Symbol Sector Weight Return Contribution
1 LLY Health Care 20.17% +23.73% +4.79%
2 HUM Health Care 3.30% +20.88% +0.69%
3 UNH Health Care 5.43% +12.24% +0.66%
4 AZN Health Care 4.18% +13.96% +0.58%
5 ABBV Health Care 4.59% +12.60% +0.58%
6 ABT Health Care 3.87% +8.72% +0.34%
7 WST Health Care 2.01% +12.69% +0.26%
8 ISRG Health Care 2.66% +7.65% +0.20%
9 ODTX Health Care 4.51% -12.87% -0.58%
10 GPCR Health Care 2.81% -40.61% -1.14%
11 GH Health Care 7.04% -19.25% -1.35%
12 NTRA Health Care 5.58% -30.20% -1.69%
13 AVBP Health Care 6.20% -61.82% -3.83%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -2.18%, versus -17.01% for the QQQ synthetic benchmark — an excess of +14.84%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +6.42%, Kurtosis +3.50%, Residual Volatility +2.72%; the largest drags came from Momentum -3.10%, Skewness -2.57%, Mid Cap -1.48%. Specific (stock-level) return contributed -8.06%.
  3. Risk attribution: Barra model volatility is 20.16% annualised; factor risk explains 71% of variance and specific risk 29%. The largest factor risk sources are Health Care 51.8%, Momentum 11.2%, Mid Cap 4.3%.
  4. Style tilt: size -0.02, momentum +0.78, volatility +0.01, liquidity +0.04; the weighted raw beta is 0.58. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+90.2 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.78%, selection +16.00% and interaction -24.90%.
  6. Concentration: the top-10 positions are 73.2% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did ORBIMED ADVISORS LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, ORBIMED ADVISORS LLC reported 112 equity positions worth $4.91B in aggregate; its largest disclosed positions were EWTX ($630.05M), VNDA ($482.66M), ELVN ($310.64M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.91B of long equity holdings across 112 positions as of 2026-Q3. Top-10 holdings account for 51.1% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →